Keith Lenden joined ARCH Venture Partners in 2017 as a Venture Partner. Keith is a seasoned entrepreneur and leader in the biotechnology and pharmaceutical space with a proven track record in company formation, executive and project leadership, business and corporate development, alliance management, and corporate and market strategy. Keith was a co-founder of Receptos, Inc., a S1P1 biology and GPCR drug discovery company acquired by Celgene for $7.2 billion in 2015, and Abide Therapeutics, Inc., a cannabinoid biology and serine hydrolase drug discovery company that entered into a build-to-buy partnership with Celgene in 2014. Keith has served in a wide range of executive and product leadership roles for both public and private biopharmaceutical companies over the years including Esperion Therapeutics, Inc., Maxygen, Inc., Acologix, Inc. and Genteric, Inc. Keith started his career in biotechnology as a consultant at LEK Consulting.
Keith earned a MBA from the Haas School of Business at the University of California, Berkeley where he was selected as a Price Institute for Entrepreneurial Studies Venture Capital Fellow. Keith also earned A.B. and B.E. degrees from the Thayer School of Engineering at Dartmouth College. Keith is also a Kauffman Fellow where he received the Jeff Timmons Leadership Award.